Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

The two blockbusters Novo Nordisk medicines are among 15 additional drugs whose prices Medicare will be allowed to negotiate with drugmakers.

Popular weight loss and diabetes drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and drug manufacturers, the ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations, the Biden ...

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

Novo's earnings results Wednesday differ from Eli Lilly's, whose stock slid on slower-than-expected sales of weight loss ...

Medicare announced Friday that it has selected 15 drugs, including the hugely popular medications Ozempic and Wegovy, used for diabetes and weight loss, as well as some blockbuster cancer ...

According to CMS, close to 2.3 million seniors enrolled in Medicare are using Novo Nordisk’s semaglutide medications branded as Ozempic, Wegovy and Rybelsus. Between November 2023 and October ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations ...

WASHINGTON -- Popular weight loss and diabetes drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and drug ...

(AP Photo/Amanda Andrade-Rhoades, File)(Amanda Andrade-Rhoades / AP) WASHINGTON — Popular weight loss and diabetes drugs like Ozempic and Wegovy have been added to Medicare’s list of ...

The move could mean savings for consumers. Weight loss drugs Ozempic and Wegovy have been added to the list of medications Medicare will be able to negotiate directly with drug manufacturers ...